Published in Br J Clin Pharmacol on March 01, 1993
The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol (1994) 0.85
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. Br J Clin Pharmacol (1995) 0.81
The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol (1991) 3.73
Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther (1989) 1.55
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther (1982) 1.46
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry (1988) 1.28
Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther (1989) 1.17
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther (1986) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol (1991) 1.00
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther (1991) 0.96
Imipramine metabolites in blood of patients during therapy and after overdose. Clin Pharmacol Ther (1983) 0.94
Prediction of steady-state behavior of metabolite from dosing of parent drug. J Pharm Sci (1980) 0.84
Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet (1977) 0.82
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol (1986) 0.81
Steady-state kinetics of imipramine in patients. Psychopharmacology (Berl) (1977) 0.80
Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med (1990) 2.96
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol (1989) 2.04
Quantitative rating of depressive states. Acta Psychiatr Scand (1975) 2.00
Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol (1992) 1.70
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol (1996) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand (1981) 1.43
Interaction between tramadol and phenprocoumon. Lancet (1997) 1.38
Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatr Scand (2000) 1.32
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain (1999) 1.28
Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) (1985) 1.27
The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther (1992) 1.26
The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther (1996) 1.26
Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Br J Clin Pharmacol (1996) 1.25
Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol (1986) 1.23
Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol (1997) 1.22
Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol (1991) 1.21
Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain (1990) 1.20
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther (1992) 1.18
Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J (1972) 1.15
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit (1993) 1.10
Imipramine treatment of painful diabetic neuropathy. JAMA (1984) 1.09
The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics (1995) 1.09
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol (1996) 1.08
Are in-patient depressives more often of the melancholic subtype? Danish University Antidepressant Group. Acta Psychiatr Scand (1998) 1.08
Drug related hospital admissions. Results from an intervention program. Eur J Clin Pharmacol (1993) 1.07
Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology (Berl) (1977) 1.07
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther (1986) 1.06
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol (1989) 1.06
Drug-related admissions to a department of medical gastroenterology. The role of self-medicated and prescribed drugs. Scand J Gastroenterol (1991) 1.04
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol (1993) 1.04
Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol (2001) 1.04
Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol (1992) 1.04
In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol (2002) 1.04
Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull (1991) 1.03
Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull (1998) 1.02
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit (1991) 1.01
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther (1990) 0.99
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther (1995) 0.99
Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med (1990) 0.98
Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther (1996) 0.98
Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol (1995) 0.98
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol (1982) 0.97
First-pass metabolism of imipramine in man. Clin Pharmacol Ther (1975) 0.97
Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand (2001) 0.96
Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol (1995) 0.96
Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol (1996) 0.96
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther (1991) 0.96
First-pass metabolism of nortriptyline in man. Clin Pharmacol Ther (1975) 0.96
The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain (2001) 0.96
Imipramine metabolites in blood of patients during therapy and after overdose. Clin Pharmacol Ther (1983) 0.94
Outpatient utilization of antidepressants: a prescription database analysis. J Affect Disord (1993) 0.94
Metabolism of tricyclic antidepressants. A review. Dan Med Bull (1974) 0.94
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos (1988) 0.93
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit (2000) 0.91
The hypoalgesic effect of imipramine in different human experimental pain models. Pain (1995) 0.91
Drug-related illness as a cause of admission to a department of respiratory medicine. Respiration (1992) 0.91
Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther (1976) 0.91
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol (1990) 0.91
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics (1999) 0.91
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol (1990) 0.90
Inappropriate use of sumatriptan: population based register and interview study. BMJ (1998) 0.90
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther (1992) 0.90
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther (1999) 0.90
Equilibrium dialysis for determination of protein binding or imipramine--evaluation of a method. Acta Pharmacol Toxicol (Copenh) (1982) 0.90
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol (1990) 0.90
d-Propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharmacol Ther (1979) 0.89
Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther (2005) 0.88
Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol (1989) 0.88
Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol (1997) 0.88
Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1994) 0.88